Soleno Therapeutics (SLNO) Enterprise Value (2016 - 2019)
Historic Enterprise Value for Soleno Therapeutics (SLNO) over the last 7 years, with Q3 2019 value amounting to -$11.2 million.
- Soleno Therapeutics' Enterprise Value fell 962.98% to -$11.2 million in Q3 2019 from the same period last year, while for Sep 2019 it was -$11.2 million, marking a year-over-year decrease of 962.98%. This contributed to the annual value of -$23.1 million for FY2018, which is 3508.19% down from last year.
- Soleno Therapeutics' Enterprise Value amounted to -$11.2 million in Q3 2019, which was down 962.98% from -$15.5 million recorded in Q2 2019.
- In the past 5 years, Soleno Therapeutics' Enterprise Value registered a high of -$2.5 million during Q2 2016, and its lowest value of -$23.1 million during Q4 2018.
- For the 5-year period, Soleno Therapeutics' Enterprise Value averaged around -$10.1 million, with its median value being -$9.5 million (2015).
- Its Enterprise Value has fluctuated over the past 5 years, first crashed by 727500.0% in 2015, then surged by 6677.29% in 2016.
- Quarter analysis of 5 years shows Soleno Therapeutics' Enterprise Value stood at -$5.5 million in 2015, then skyrocketed by 50.39% to -$2.7 million in 2016, then crashed by 527.29% to -$17.1 million in 2017, then plummeted by 35.08% to -$23.1 million in 2018, then surged by 51.4% to -$11.2 million in 2019.
- Its last three reported values are -$11.2 million in Q3 2019, -$15.5 million for Q2 2019, and -$19.4 million during Q1 2019.